RxSight Adjusts FY26 Revenue Outlook to $129.24M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 hours ago
0mins
Consensus $129.24M. The company said that the FY26 revenue view is inclusive of RxSight sales and revenue recognized from the RxSight Alcon Strategic Collaboration, comprised of: Sales of $110M-$120M, below previous guidance of $120M-$135M; Collaboration Agreement revenue of $30M-$40M, subject to the terms and conditions described in the Current Report on Form 8-K filed with the Securities and Exchange Commission on or about the date hereof; Gross margin of 73% to 75%, above previous guidance of 70% to 72%; and Operating expense at the high-end of $150M-$160M, in line with previous guidance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RXST?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RXST
Wall Street analysts forecast RXST stock price to rise
9 Analyst Rating
1 Buy
6 Hold
2 Sell
Hold
Current: 5.600
Low
8.00
Averages
10.25
High
14.00
Current: 5.600
Low
8.00
Averages
10.25
High
14.00
About RXST
RxSight, Inc. is a commercial-stage medical technology company engaged in providing customized vision to patients following cataract surgery. Its RxSight Light Adjustable Lens system (RxSight system) is a cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system is composed of RxSight Light Adjustable Lens (LAL), RxSight Light Delivery Device (LDD) and related accessories. The LAL is an intraocular lens (IOL) made from the silicone-based photosensitive material that undergoes controlled changes in refractive power when exposed to specific ultraviolet (UV) light patterns generated by the LDD. Its LAL uses a silicone formulation that enables changing the mechanical and optical properties of the lens following implantation. The LDD uses software and algorithms to deliver a short UV light exposure treatment that polymerizes specific portions of the lens and allows doctors to adjust spherical and cylindrical refraction.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
RxSight Announces Preliminary Q2 2026 Financial Results and Product Pipeline Updates
- Financial Performance Forecast: RxSight anticipates total revenue for Q2 2026 to be approximately $32 to $34 million, including $5 to $7 million from the RxSight-Alcon strategic collaboration, indicating robust market performance.
- Product Sales Overview: The company reported sales of about $27 million, comprising 24,917 Light Adjustable Lens (LAL®) units and 11 Light Delivery Devices (LDD™), reflecting sustained demand for its innovative products in the market.
- Strategic Collaboration Progress: The partnership with Alcon aims to develop and commercialize light-adjustable Presbyopia-Correcting Intraocular Lenses, which is expected to drive future revenue growth and enhance market share, further solidifying RxSight's leadership in the ophthalmic device sector.
- 2026 Guidance Update: The company revised its full-year revenue guidance for 2026 to $140 to $160 million; despite a downward adjustment in sales expectations, the gross margin forecast has improved to 73% to 75%, demonstrating proactive strategies in cost management and profitability enhancement.
See More
RxSight Q2 2026 Earnings Call Insights
- Revenue Guidance Revision: RxSight anticipates full-year 2026 revenue between $140 million and $160 million, including $30 million to $40 million from the strategic collaboration with Alcon, indicating a cautious optimism about future growth amidst market pressures.
- Increased Market Challenges: The company expects total revenue for Q2 to be approximately $32 million to $34 million, reflecting a 20% decline year-over-year, primarily due to competitive trialing activities and pressured consumer sentiment leading to a slowdown in overall procedure activity.
- Product Innovation Progress: RxSight is developing the next-generation LAL Toric lens designed to combine built-in toric correction with postoperative refinement capabilities, enhancing product competitiveness and addressing market needs.
- Sales Force Investment: The company plans to increase investments in its U.S. LAL sales force to tackle market challenges and improve customer re-engagement, even as operating expenses are expected to remain at the high end of $150 million to $160 million.
See More
RxSight Reports Q2 2026 Preliminary Results and Updates Guidance
- Preliminary Financial Outlook: RxSight anticipates Q2 2026 revenue between $32 million and $34 million, with approximately $5 million to $7 million from the Alcon collaboration, indicating a decline from $33.6 million year-over-year, reflecting competitive pressures in the market.
- Core Product Sales: The company reported core product sales of $27 million, selling 24,917 Light Adjustable Lens (LAL) units and 11 Light Delivery Devices (LDD), down from 27,380 LALs and 40 LDDs sold in Q2 2025, highlighting weakened demand.
- Strategic Collaboration Agreement: The partnership with Alcon combines light-adjustable technology with PCIOL optical designs, providing RxSight with a $60 million upfront payment and potential additional $140 million upon achieving development milestones, enhancing the company's liquidity.
- 2026 Performance Guidance: The company expects full-year 2026 revenue in the range of $140 million to $160 million, but excluding Alcon-related revenue, forecasts sales of $110 million to $120 million, below previous guidance, indicating challenges in the market environment.
See More
Alcon Partners with RxSight to Develop Adjustable Intraocular Lenses
- Collaboration Agreement: Alcon has entered a non-exclusive collaboration with RxSight, which will receive an upfront payment of $60 million to support the development of adjustable presbyopia-correcting intraocular lenses, with an additional $140 million contingent on achieving specific milestones, bringing the total potential deal value to $200 million.
- Technological Integration: This partnership aims to combine RxSight's post-operative light-adjustable technology with Alcon's optical designs for intraocular lenses, enabling more precise visual adjustments for cataract patients opting for these lenses, thereby enhancing surgical outcomes.
- Market Commercialization Strategy: Alcon will lead global commercialization while RxSight will handle development and manufacturing, with RxSight eligible for royalties on net sales, a division of responsibilities that is expected to accelerate product launch and expand market share.
- Stock Performance Overview: Alcon's stock has traded between $61.83 and $92.55 over the past year, closing at $68.33, indicating cautious optimism in the market regarding the collaboration's prospects; RxSight's stock has fluctuated between $4.48 and $13.36, closing at $5.60, reflecting market interest in its technology.
See More
Alcon and RxSight Collaborate on Adjustable Intraocular Lenses Development
- Collaboration Agreement: Alcon and RxSight have entered a non-exclusive partnership to jointly develop adjustable presbyopia-correcting intraocular lenses (PCIOLs), enhancing visual outcomes for cataract patients by integrating their respective technologies.
- Financial Backing: RxSight will receive a $60 million upfront payment to initiate development, with potential additional payments of up to $140 million tied to development and regulatory milestones, significantly improving its liquidity.
- Market Leadership: Under the agreement, Alcon will lead global commercialization while RxSight focuses on development and manufacturing, receiving royalties on net sales, which will expedite the product's market entry.
- Innovative Technology Outlook: Alcon CEO David Endicott stated that the combination with RxSight's technology will provide surgeons greater confidence in refining post-surgery visual outcomes, further solidifying Alcon's leadership position in the ophthalmic market.
See More
RxSight Updates 2026 Revenue Outlook Amid Q2 Preliminary Results
- Q2 Revenue Expectations: RxSight anticipates preliminary Q2 revenue between $32 million and $34 million, including $5 million to $7 million from its strategic collaboration with Alcon, indicating early success in partnerships that may lay the groundwork for future growth.
- Product Sales Data: Expected product sales are approximately $27 million, comprising 24,917 Light Adjustable Lens units and 11 Light Delivery Devices, reflecting stable market demand and enhancing the company's position in the ophthalmic device sector.
- Cash Flow Status: As of June 30, the company reported cash, cash equivalents, and short-term investments totaling about $209 million, ensuring financial flexibility for future R&D and market expansion, supporting its long-term strategic goals.
- Revenue Outlook Adjustment: RxSight revised its 2026 revenue outlook to $140 million to $160 million, with product sales projected at $110 million to $120 million; although standalone sales guidance was lowered, gross margin expectations were raised to 73%-75%, highlighting a focus on profitability.
See More
RxSight Announces Preliminary Q2 2026 Financial Results and Product Pipeline Updates
- Financial Performance Forecast: RxSight anticipates total revenue for Q2 2026 to be approximately $32 to $34 million, including $5 to $7 million from the RxSight-Alcon strategic collaboration, indicating robust market performance.
- Product Sales Overview: The company reported sales of about $27 million, comprising 24,917 Light Adjustable Lens (LAL®) units and 11 Light Delivery Devices (LDD™), reflecting sustained demand for its innovative products in the market.
- Strategic Collaboration Progress: The partnership with Alcon aims to develop and commercialize light-adjustable Presbyopia-Correcting Intraocular Lenses, which is expected to drive future revenue growth and enhance market share, further solidifying RxSight's leadership in the ophthalmic device sector.
- 2026 Guidance Update: The company revised its full-year revenue guidance for 2026 to $140 to $160 million; despite a downward adjustment in sales expectations, the gross margin forecast has improved to 73% to 75%, demonstrating proactive strategies in cost management and profitability enhancement.
See More
RxSight Q2 2026 Earnings Call Insights
- Revenue Guidance Revision: RxSight anticipates full-year 2026 revenue between $140 million and $160 million, including $30 million to $40 million from the strategic collaboration with Alcon, indicating a cautious optimism about future growth amidst market pressures.
- Increased Market Challenges: The company expects total revenue for Q2 to be approximately $32 million to $34 million, reflecting a 20% decline year-over-year, primarily due to competitive trialing activities and pressured consumer sentiment leading to a slowdown in overall procedure activity.
- Product Innovation Progress: RxSight is developing the next-generation LAL Toric lens designed to combine built-in toric correction with postoperative refinement capabilities, enhancing product competitiveness and addressing market needs.
- Sales Force Investment: The company plans to increase investments in its U.S. LAL sales force to tackle market challenges and improve customer re-engagement, even as operating expenses are expected to remain at the high end of $150 million to $160 million.
See More
RxSight Reports Q2 2026 Preliminary Results and Updates Guidance
- Preliminary Financial Outlook: RxSight anticipates Q2 2026 revenue between $32 million and $34 million, with approximately $5 million to $7 million from the Alcon collaboration, indicating a decline from $33.6 million year-over-year, reflecting competitive pressures in the market.
- Core Product Sales: The company reported core product sales of $27 million, selling 24,917 Light Adjustable Lens (LAL) units and 11 Light Delivery Devices (LDD), down from 27,380 LALs and 40 LDDs sold in Q2 2025, highlighting weakened demand.
- Strategic Collaboration Agreement: The partnership with Alcon combines light-adjustable technology with PCIOL optical designs, providing RxSight with a $60 million upfront payment and potential additional $140 million upon achieving development milestones, enhancing the company's liquidity.
- 2026 Performance Guidance: The company expects full-year 2026 revenue in the range of $140 million to $160 million, but excluding Alcon-related revenue, forecasts sales of $110 million to $120 million, below previous guidance, indicating challenges in the market environment.
See More
Alcon Partners with RxSight to Develop Adjustable Intraocular Lenses
- Collaboration Agreement: Alcon has entered a non-exclusive collaboration with RxSight, which will receive an upfront payment of $60 million to support the development of adjustable presbyopia-correcting intraocular lenses, with an additional $140 million contingent on achieving specific milestones, bringing the total potential deal value to $200 million.
- Technological Integration: This partnership aims to combine RxSight's post-operative light-adjustable technology with Alcon's optical designs for intraocular lenses, enabling more precise visual adjustments for cataract patients opting for these lenses, thereby enhancing surgical outcomes.
- Market Commercialization Strategy: Alcon will lead global commercialization while RxSight will handle development and manufacturing, with RxSight eligible for royalties on net sales, a division of responsibilities that is expected to accelerate product launch and expand market share.
- Stock Performance Overview: Alcon's stock has traded between $61.83 and $92.55 over the past year, closing at $68.33, indicating cautious optimism in the market regarding the collaboration's prospects; RxSight's stock has fluctuated between $4.48 and $13.36, closing at $5.60, reflecting market interest in its technology.
See More
Alcon and RxSight Collaborate on Adjustable Intraocular Lenses Development
- Collaboration Agreement: Alcon and RxSight have entered a non-exclusive partnership to jointly develop adjustable presbyopia-correcting intraocular lenses (PCIOLs), enhancing visual outcomes for cataract patients by integrating their respective technologies.
- Financial Backing: RxSight will receive a $60 million upfront payment to initiate development, with potential additional payments of up to $140 million tied to development and regulatory milestones, significantly improving its liquidity.
- Market Leadership: Under the agreement, Alcon will lead global commercialization while RxSight focuses on development and manufacturing, receiving royalties on net sales, which will expedite the product's market entry.
- Innovative Technology Outlook: Alcon CEO David Endicott stated that the combination with RxSight's technology will provide surgeons greater confidence in refining post-surgery visual outcomes, further solidifying Alcon's leadership position in the ophthalmic market.
See More
RxSight Updates 2026 Revenue Outlook Amid Q2 Preliminary Results
- Q2 Revenue Expectations: RxSight anticipates preliminary Q2 revenue between $32 million and $34 million, including $5 million to $7 million from its strategic collaboration with Alcon, indicating early success in partnerships that may lay the groundwork for future growth.
- Product Sales Data: Expected product sales are approximately $27 million, comprising 24,917 Light Adjustable Lens units and 11 Light Delivery Devices, reflecting stable market demand and enhancing the company's position in the ophthalmic device sector.
- Cash Flow Status: As of June 30, the company reported cash, cash equivalents, and short-term investments totaling about $209 million, ensuring financial flexibility for future R&D and market expansion, supporting its long-term strategic goals.
- Revenue Outlook Adjustment: RxSight revised its 2026 revenue outlook to $140 million to $160 million, with product sales projected at $110 million to $120 million; although standalone sales guidance was lowered, gross margin expectations were raised to 73%-75%, highlighting a focus on profitability.
See More
